Inhaled steroids with and without regular salmeterol for asthma: serious adverse events

Abstract

Editorial group: Cochrane Airways Group. Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 12, 2018.

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials

“…This conclusion is also in agreement with findings from recent cumulative reviews of ICS/LABA vs. ICS trials in asthma focused on specific LABA products formoterol [26] and salmeterol [27], where overall mortality rate in the ICS/LABA arms was not significantly different from the rate in the ICS arms, and was equal to 1 death per 1000 patients treated for 26 weeks (i.e., 2 deaths per 1000 patient-years, with the same estimate for ICS/formoterol and ICS/salmeterol products).…”

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials

“…This conclusion is also in agreement with findings from recent cumulative reviews of ICS/LABA vs. ICS trials in asthma focused on specific LABA products formoterol [26] and salmeterol [27], where overall mortality rate in the ICS/LABA arms was not significantly different from the rate in the ICS arms, and was equal to 1 death per 1000 patients treated for 26 weeks (i.e., 2 deaths per 1000 patient-years, with the same estimate for ICS/formoterol and ICS/salmeterol products).…”

Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)

“… 10 Some studies reported that for every 1000 children treated with ICS for 23 weeks, 15 children experienced severe adverse effects. 26 …”

The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and children

“…[ 87 128 129 130 ] Reliever therapy is recommended in the form of SABA (with or without ICS) whenever a maintenance fixed-dose combination of ICS/non-formoterol LABA or in the form of ICS/formoterol whenever a maintenance fixed-dose ICS/formoterol combination is prescribed. [ 131 132 ] Physicians should ensure the adherence of patients to this regimen[ 106 ] Alternative options: The addition of LTRA to a low-dose ICS is another option, especially in patients with concomitant rhinitis (Evidence A)[ 133 134 135 ] Continuation of ICS as a monotherapy by increasing the dose to the medium level is generally a less effective strategy (Evidence A). [ 136 137 ] …”

“…[ 87 128 129 130 ] Reliever therapy is recommended in the form of SABA (with or without ICS) whenever a maintenance fixed-dose combination of ICS/non-formoterol LABA or in the form of ICS/formoterol whenever a maintenance fixed-dose ICS/formoterol combination is prescribed. [ 131 132 ] Physicians should ensure the adherence of patients to this regimen[ 106 ]…”

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials

“…This conclusion is also in agreement with findings from recent cumulative reviews of ICS/LABA vs. ICS trials in asthma focused on specific LABA products formoterol [26] and salmeterol [27], where overall mortality rate in the ICS/LABA arms was not significantly different from the rate in the ICS arms, and was equal to 1 death per 1000 patients treated for 26 weeks (i.e., 2 deaths per 1000 patient-years, with the same estimate for ICS/formoterol and ICS/salmeterol products).…”

Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)

“… 10 Some studies reported that for every 1000 children treated with ICS for 23 weeks, 15 children experienced severe adverse effects. 26 …”

The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and children

“…[ 87 128 129 130 ] Reliever therapy is recommended in the form of SABA (with or without ICS) whenever a maintenance fixed-dose combination of ICS/non-formoterol LABA or in the form of ICS/formoterol whenever a maintenance fixed-dose ICS/formoterol combination is prescribed. [ 131 132 ] Physicians should ensure the adherence of patients to this regimen[ 106 ] Alternative options: The addition of LTRA to a low-dose ICS is another option, especially in patients with concomitant rhinitis (Evidence A)[ 133 134 135 ] Continuation of ICS as a monotherapy by increasing the dose to the medium level is generally a less effective strategy (Evidence A). [ 136 137 ] …”

“…[ 87 128 129 130 ] Reliever therapy is recommended in the form of SABA (with or without ICS) whenever a maintenance fixed-dose combination of ICS/non-formoterol LABA or in the form of ICS/formoterol whenever a maintenance fixed-dose ICS/formoterol combination is prescribed. [ 131 132 ] Physicians should ensure the adherence of patients to this regimen[ 106 ]…”

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials

“…This conclusion is also in agreement with findings from recent cumulative reviews of ICS/LABA vs. ICS trials in asthma focused on specific LABA products formoterol [26] and salmeterol [27], where overall mortality rate in the ICS/LABA arms was not significantly different from the rate in the ICS arms, and was equal to 1 death per 1000 patients treated for 26 weeks (i.e., 2 deaths per 1000 patient-years, with the same estimate for ICS/formoterol and ICS/salmeterol products).…”

Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)

“… 10 Some studies reported that for every 1000 children treated with ICS for 23 weeks, 15 children experienced severe adverse effects. 26 …”

The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and children

“…[ 87 128 129 130 ] Reliever therapy is recommended in the form of SABA (with or without ICS) whenever a maintenance fixed-dose combination of ICS/non-formoterol LABA or in the form of ICS/formoterol whenever a maintenance fixed-dose ICS/formoterol combination is prescribed. [ 131 132 ] Physicians should ensure the adherence of patients to this regimen[ 106 ] Alternative options: The addition of LTRA to a low-dose ICS is another option, especially in patients with concomitant rhinitis (Evidence A)[ 133 134 135 ] Continuation of ICS as a monotherapy by increasing the dose to the medium level is generally a less effective strategy (Evidence A). [ 136 137 ] …”

“…[ 87 128 129 130 ] Reliever therapy is recommended in the form of SABA (with or without ICS) whenever a maintenance fixed-dose combination of ICS/non-formoterol LABA or in the form of ICS/formoterol whenever a maintenance fixed-dose ICS/formoterol combination is prescribed. [ 131 132 ] Physicians should ensure the adherence of patients to this regimen[ 106 ]…”